3-piperidino-1-(3-nitrophenyl)propan-1-one | 30237-09-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-piperidino-1-(3-nitrophenyl)propan-1-one
• 英文别名: 1-(3-Nitrophenyl)-3-piperidin-1-ylpropan-1-one
• CAS: 30237-09-3
• 化学式: C₁₄H₁₈N₂O₃
• 分子量: 262.309
• InChiKey: OMMLHBLYTXQWIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-溴苯丙酮 在 硝酸 作用下， 以 乙腈 为溶剂， 反应 0.08h， 生成 3-piperidino-1-(3-nitrophenyl)propan-1-one
  参考文献：
  名称：

  Popov, A. F.; Piskunova, Zh. P.; Matvienko, V. N., Journal of Organic Chemistry USSR (English Translation), 1986, vol. 22, # 10, p. 1918 - 1921

  摘要：

  DOI：

文献信息

• Hypolipidemic Activity of 3-Amino-1-(2,3,4-mononitro-, mono-, or dihalophenyl)propan-1-ones in Rodents
  作者：Yunsheng Huang、Iris H. Hall

  DOI：10.1002/ardp.19963290703

  日期：——

  A series of 3‐amino‐1‐(2,3,4‐mononitro‐, mono‐, or dihalophenyl)propan‐1‐ones were synthesized and shown to be effective in lowering both serum cholesterol and triglyceride levels significantly in CF1 mice and Sprague‐Dawley rats. All analogs showed better activity than the standard drugs, lovastatin and clofibrate, in reducing the serum cholesterol and triglyceride levels in mice at 8 mg/kg/day intraperitoneally

  合成了一系列 3-氨基-1-（2,3,4-单硝基-、单-或二卤代苯基）丙-1-，并显示可有效降低 CF1 小鼠的血清胆固醇和甘油三酯水平，并且Sprague-Dawley 提供建议。所有类似物都显示出比标准药物洛伐他汀和氯贝特更好的活性，以 8 毫克/千克/天的剂量腹膜内降低小鼠的血清胆固醇和甘油三酯水平。最好的活性类似物，3-吗啉-1-（3-硝基苯基）丙-1-一（4）和3-哌啶基-1-（3-硝基苯基）丙-1-一（5），表现出58%和67在 CF1 小鼠中以 8mg/kg/天腹膜内给药 16 天后，血清胆固醇水平分别降低 %，血清甘油三酯水平分别降低 42% 和 46%。在 Sprague ‐ Dawley 大鼠中以 8 mg/kg/天口服给药，两种化合物（4 和 5）都显着降低了血清胆固醇和甘油三酯水平。化合物 4 显着降低了大鼠组织的脂质水平，而化合物 5 的作用较小。乳糜微粒、VLDL
• Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
  申请人：Keller T. Bradley

  公开号：US20060003975A1

  公开（公告）日：2006-01-05

  Novel methods and combinations for the treatment and/or prophylaxis of a pathologic condition in a subject, wherein the methods comprise the administration of one or more HMG Co-A reductase inhibitors and one or more aldosterone receptor antagonists, and the combinations comprise one or more HMG Co-A reductase inhibitors and one or more of said aldosterone receptor antagonists.

  用于治疗和/或预防受试者病理状况的新方法和组合，其中所述方法包括施用一种或多种 HMG Co-A 还原酶抑制剂和一种或多种醛固酮受体拮抗剂，所述组合包括一种或多种 HMG Co-A 还原酶抑制剂和一种或多种所述醛固酮受体拮抗剂。
• [EN] COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA<br/>[FR] POLYTHERAPIE POUR TRAITER L'HYPERCHOLESTEROLEMIE
  申请人：GELTEX PHARMA INC

  公开号：WO2000069446A1

  公开（公告）日：2000-11-23

  The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.
• Popov, A. F.; Piskunova, Zh. P.; Matvienko, V. N., Journal of Organic Chemistry USSR (English Translation), 1986, vol. 22, # 10, p. 1918 - 1921
  作者：Popov, A. F.、Piskunova, Zh. P.、Matvienko, V. N.

  DOI：——

  日期：——